Pancreatic Cancer Research

ResearcherThomas Jefferson UniversityActive in the last 2 years

Alok Bhushan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4800-5009; OpenAlex author ID A5000506692. Sources: OpenAlex.

Their work

Papers
3 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
4
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: 1 paper

Papers 3

  1. Combination Treatment of Biochanin A and Atorvastatin Alters Mitochondrial Bioenergetics, Modulating Cell Metabolism and Inducing Cell Cycle Arrest in Pancreat… Last author DOI 10.21873/anticanres.17038↗
  2. Metabolic plasticity imparts erlotinib-resistance in pancreatic cancer by upregulating glucose-6-phosphate dehydrogenase. First author DOI 10.1186/s40170-020-00226-5↗
  3. Biochanin A reduces pancreatic cancer survival and progression. Last author DOI 10.1097/cad.0000000000000044↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Vilas S. Desai · 1 shared paper, 2024 · strength 0.26
  2. Vikas Bhardwaj · 2 shared papers, 2014–2020 · strength 0.19
  3. Neha Sharma · 1 shared paper, 2020 · strength 0.15
  4. Aditi Jain · 1 shared paper, 2014 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.